Whalesbook
Goldline Pharma IPO Draws Strong Demand, Focuses on Debt Repayment
Goldline Pharmaceutical's initial public offering drew strong investor interest, closing its first day of bidding with an overall subscription of 20.79 times. This demand was driven mainly by retail investors, whose portion was subscribed an impressive 34.07 times, with non-institutional investors also showing strong interest at 18.07 times. The Qualified Institutional Buyer (QIB) segment saw a lower interest at 1.31 times.
The company is raising Rs 11.61 crore through this offering, with shares priced between Rs 41 and Rs 43. A substantial Rs 8.35 crore of the IPO proceeds is earmarked for the repayment of specific borrowings, indicating a priority on strengthening its balance sheet over immediate expansion. Using IPO funds for debt reduction is a common strategy in India, helping companies lower interest costs and improve profits.
RFBL Flexi Pack IPO Funds Expansion Projects
In contrast, RFBL Flexi Pack's public issue saw a more modest, yet positive, first-day subscription of 1.18 times. Non-institutional investors led demand with 1.59 times their reserved quota, followed by QIBs (1.11x) and retail investors (1.07x). The company plans to raise Rs 35.33 crore at a price band of Rs 47-50 per share.
The allocation strategy here is growth-oriented, with Rs 12.4 crore designated for acquiring land for and establishing a new manufacturing facility in Gujarat, and an additional Rs 17.76 crore aimed at boosting working capital needs. This growth-oriented approach aligns with the packaging sector's expected expansion, fueled by demand from FMCG and pharmaceutical sectors.
Valuation and Sector Outlook
The Indian IPO market in early May 2026 sees investors increasingly selective, prioritizing quality and pricing amid global uncertainties. While Goldline's offering aims to improve its financial health, its asset-light model relies on third-party manufacturers. Its pre-IPO P/E ratio stands at approximately 9.75x, rising to 15.19x post-IPO.
RFBL's post-IPO P/E of about 15.19x at the upper band is comparable to peers like Uma Converter and Sabar Flex. However, RFBL's high leverage (Debt/Equity of 0.80) and substantial trading revenue (62%) require careful consideration. The packaging sector is expected to grow, with the plastic film packaging market projected for significant expansion by 2035.
Goldline & RFBL: Key Risks and Challenges
Goldline's substantial allocation of IPO funds to debt repayment suggests a focus on managing past obligations rather than immediate expansion. While deleveraging can boost profits, it raises questions about organic growth and reliance on external manufacturers. Goldline also faces active tax proceedings totaling around ₹3.34 crore, which could lead to future liabilities. Its asset-light model reduces fixed costs but means relying on third-party manufacturers, introducing supply chain and quality control risks. In the competitive pharmaceutical market, scale and in-house R&D are often key differentiators.
RFBL Flexi Pack's main risks include high customer concentration, with its top five customers making up 93.85% of revenue, and a lack of formal long-term contracts. A shift towards trading, now over 62% of revenue, lowers margins compared to manufacturing. RFBL's manufacturing capacity utilization is also low at 52%, even with expansion plans. Negative operating cash flow in FY25, requiring financing, and past statutory filing delays raise governance and financial management concerns. The valuation, based on manufacturing multiples despite a large trading component, offers little room for error.
IPO Closing and Market Watch
Both companies are set to close their IPO subscriptions on May 14, 2026. The market's reaction to the listing performance of these two IPOs, showcasing different strategies, will offer insights into investor appetite for varying risk-reward profiles. The Indian IPO market has matured, with investors favoring companies with clear capital allocation and strong fundamentals over hype.